OPTISCAN IMAGING LIMITED (ASX: OIL)
Health care · News and insights
OIL: $0.145 -6.45% · MC: $162M
Latest OIL announcements
2026-11-17 · Health care
OIL: $0.145 -6.45% · MC: $162M
Optiscan Imaging says it filed US regulatory applications for its InForm and InVue human imaging devices in October, with clearances anticipated from October next year, subject to review. The company plans to place consoles at up to five US reference sites before expanding to its first customer accounts. Its first own-brand clinical product, InSpecta, launched in the US veterinary market in July.
Updated 2026-11-17 10:38
Sources
Bell Potter Healthcare Conference PresentationComments
2026-11-05 · Health care
OIL: $0.155 +3.33% · MC: $162M
Optiscan Imaging has appointed Clermont Group executive Russell Low as a non-executive director, replacing Sean Gardiner, whose resignation is effective today. Low is Clermont’s president and Singapore country head and previously chaired Vietnamese hospital operator Hoan My Medical Corporation. The appointment comes after Optiscan reported lodging US regulatory submissions for its InForm and InVue devices, which remain subject to review.
Updated 2026-11-05 15:48
Sources
Optiscan Strengthens Board with Appointment of Russell LowComments
2026-11-04 · Health care
OIL: $0.150 -6.25% · MC: $162M
Optiscan Imaging reported that 200,000 unquoted options lapsed because their conditions were not met or could no longer be met. No options remain in that class following the cessation.
Updated 2026-11-04 15:03
Sources
Notification of cessation of securities - OILComments
2026-10-30 · Health care
OIL: $0.155 +3.33% · MC: $162M
Optiscan says it lodged U.S. FDA applications for its InForm digital pathology and InVue precision surgery devices shortly after quarter-end, moving both into formal review; U.S. market entry remains subject to clearance. The company also signed two Mayo Clinic research agreements and launched its InSpecta veterinary device in the U.S. during the quarter.
Updated 2026-10-30 12:01
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments